Overview of the DIG trial
| Autor: | Joseph F. Collins, Rekha Garg, Debra Egan, William O. Williford, Nancy L. Geller, Salim Yusuf |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Canada
Digoxin medicine.medical_specialty Cardiotonic Agents Randomization Heart disease law.invention Randomized controlled trial law medicine Humans Multicenter Studies as Topic Intensive care medicine Randomized Controlled Trials as Topic Heart Failure Pharmacology Ejection fraction business.industry Public health medicine.disease United States Clinical trial Organization and Administration Research Design Heart failure Emergency medicine business medicine.drug |
| Zdroj: | Controlled Clinical Trials. 24:S269-S276 |
| ISSN: | 0197-2456 |
| DOI: | 10.1016/s0197-2456(03)00104-1 |
| Popis: | Congestive heart failure is a major public health problem in the United States, Canada, and other Western countries. The Digitalis Investigation Group (DIG) trial was a randomized, double-blind placebo-controlled trial that evaluated the effects of digoxin on all-cause mortality and on hospitalization for heart failure in patients with heart failure and left ventricular ejection fraction < or =0.45 with normal sinus rhythm. It was designed as a large simple trial. There were 6800 patients entered into the main study over a 31.5-month recruitment period at 302 participating centers in the United States and Canada. All patients were followed for a minimum of 28 months. In order for this study to succeed, many groups had to work together successfully. In this supplement, we present practical aspects of organizing and conducting a large simple trial such as DIG. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect